Home/Pipeline/RTR242

RTR242

Alzheimer's Disease

Proof of ConceptActive

Key Facts

Indication

Alzheimer's Disease

Phase

Proof of Concept

Status

Active

Company

Retro Biosciences

About Retro Biosciences

Retro Biosciences is an ambitious, privately-held biotech focused on longevity, aiming to add a decade of healthy human lifespan by targeting the root mechanisms of aging. The company has built a diversified preclinical pipeline centered on four core technology platforms: hematopoietic stem cell (HSC) reprogramming, autophagy enhancement, microglia therapeutics, and in vivo tissue reprogramming. With a team of over 60 and advised by prominent longevity researchers, Retro is pursuing a high-risk, high-reward strategy to translate aging biology into human therapeutics, operating in a capital-intensive, pre-revenue stage.

View full company profile

Therapeutic Areas

Longevity Age-related Diseases Alzheimer's Disease Blood Disorders Osteoarthritis Age-related Hearing Loss CNS Conditions

Other Alzheimer's Disease Drugs

Drug	Company	Phase	Status
NUZ-001	Neurizon Therapeutics	Preclinical	Active
ALZN002	Alzamend Neuro	Preclinical	Research
P021	Phanes Biotech	Preclinical	Active
PB43D	Phanes Biotech	Preclinical	Active
UB-311	Vaxxinity	Phase 2	Active
Lecanemab	BioArctic	Launched	Active (Commercial)
BAN2401	BioArctic	Preclinical	Active
Undisclosed Programs	johnson-and-johnson-innovative-medicine	Pipeline	Active
MK-6240 (florquinitau)	Lantheus Medical Imaging	Regulatory Filing	Filed
NAV-4694 (flutafuranol)	Lantheus Medical Imaging	Phase 3	Active
LNTH-2620/PI-2620	Lantheus Medical Imaging	Phase 3	Recruiting
itMSCs	Stemedica Cell Technologies	Clinical Development	Active